InvivoGen has developed cellular assays to investigate immune checkpoint (IC) modulation.
These assays were specifically designed to provide a biologically relevant, sensitive, and well-controlled alternative to the use of primary human T cells for antagonist or agonist screening of the:
– 4-1BB/4-1BBL axis
– CD27/CD70 axis
– CTLA4/CD80 axis
– ICOS/ICOS-L axis
– PD-1/PD-L1 axis
– PD-1/PD-L1 and CTLA4/CD80 axes
– PD-1/PD-L1 and PD-1/PD-L2 axes
Depending on your research needs, you may choose from:
- Jurkat-Raji 4-1BB/4-1BBL Bio-IC™:
A pair of cell lines for the screening of 4-1BB or 4-1BBL antagonists - Jurkat-Raji CD27/CD70-L Bio-IC™:
A pair of cell lines for the screening of CD27 or CD70 antagonists - Jurkat-Raji CTLA4/CD80-L Bio-IC™:
A pair of cell lines for the screening of CTLA4 antagonists - Jurkat-Raji ICOS/ICOS-L Bio-IC™:
A pair of cell lines for the screening of ICOS or ICOS-L antagonists - Jurkat-Raji PD-1/PD-L1 Bio-IC™:
A pair of cell lines for the screening of PD-1 or PD-L1 antagonists - Jurkat-Raji (PD-1/CTLA4)/PD-L1 Bio-IC™:
A pair of cell lines for the screening of combinations of PD-1/PD-L1 and CTLA4/CD80 antagonists - Jurkat-Raji PD-1/PD-L2 Bio-IC™:
A pair of cell lines for the screening of combinations of PD-1/PD-L1 and PD-1/PD-L2 antagonists
- Jurkat-Lucia™ hICOS:
A single effector cell line for the screening of ICOS agonists - Jurkat-Lucia™ hCD27:
A single effector cell line for the screening of CD27 agonists - Jurkat-Lucia™ h4-1BB:
A single effector cell line for the screening of 4-1BB agonists
Applications
- Screening of IC antagonists:
The Bio-IC™ paired cell lines allow the mimicking of the immune synapse between T cells and antigen-presenting cells through the interaction of cell surface molecules delivering T cell activation and concomitant inhibitory checkpoint signals. In the presence of a potent IC antagonist, there is Lucia production. - Screening of IC agonists:
The single effector cell line assay features the surface expression of an activatory IC receptor and CD3ζ chain fusion protein. The engagement of the fusion protein drives T-cell activation. In the presence of a potent IC agonist, there is Lucia production.
Assay principle
These assays rely on the monitored activation of T cells, which derive from the human Jurkat-Lucia™ NFAT reporter cell line. They stably express the Lucia luciferase reporter gene under the control of an ISG54 minimal promoter fused to six NFAT response elements. Activation of these cells is measured as a Lucia bioluminescent signal using the appropriate detection reagent QUANTI-Luc™ 4 Lucia/Gaussia.
